arrow
A

Anne M.L. Jansen

university medical cancer center utrecht
H指数:10
被引数:674

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol

曲美替尼用于NRAS突变肿瘤:药物重定位计划的结果

2026-06-010
PRE
Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

奥拉帕利用于携带同源重组修复基因突变的肿瘤患者:来自药物再发现方案的结果

2025-10-160
OAAI
Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnostics

通过一种新的分析方法对实体瘤进行全面的基因组分析,以进行临床诊断中的广泛分析

2025-01-310
OAAI
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol

克唑替尼治疗MET突变的非小细胞肺癌的安全性、有效性和生物标志物分析 -- 来自药物再发现方案的结果

2024-10-010
PRE
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy
2024-05-151
PRE
Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP)
2023-10-011
PRE
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

durvalumab在错配修复缺陷或微卫星不稳定性高的实体瘤患者中的疗效,安全性和生物标志物分析

2023-03-049
OAAI
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

药物再发现方案 (DRUP) 中的罕见癌症患者受益于基因组学指导的治疗

2022-01-1837
OAAI
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types
2021-09-0220
OA